<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Odera DO</submitter><funding>National Institute for Health Research (NIHR)</funding><funding>Wellcome Trust</funding><pagination>eabn5993</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616656</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(682)</volume><pubmed_abstract>Natural killer (NK) cells are potent immune effectors that can be activated via antibody-mediated Fc receptor engagement. Using multiparameter flow cytometry, we found that NK cells degranulate and release IFN-γ upon stimulation with antibody-opsonized &lt;i>Plasmodium falciparum&lt;/i> merozoites. Antibody-dependent NK (Ab-NK) activity was largely strain transcending and enhanced invasion inhibition into erythrocytes. Ab-NK was associated with the successful control of parasitemia after experimental malaria challenge in African adults. In an independent cohort study in children, Ab-NK increased with age, was boosted by concurrent &lt;i>P. falciparum&lt;/i> infections, and was associated with a lower risk of clinical episodes of malaria. Nine of the 14 vaccine candidates tested induced Ab-NK, including some less well-characterized antigens: P41, P113, MSP11, RHOPH3, and &lt;i>Pf&lt;/i>_11363200. These data highlight an important role of Ab-NK activity in immunity against malaria and provide a potential mechanism for evaluating vaccine candidates.</pubmed_abstract><journal>Science translational medicine</journal><pubmed_title>Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.</pubmed_title><pmcid>PMC7616656</pmcid><funding_grant_id>16/136/33</funding_grant_id><funding_grant_id>107499</funding_grant_id><pubmed_authors>Mwai K</pubmed_authors><pubmed_authors>Diehl S</pubmed_authors><pubmed_authors>Bejon P</pubmed_authors><pubmed_authors>Rosenkranz M</pubmed_authors><pubmed_authors>Ooko M</pubmed_authors><pubmed_authors>Winterberg M</pubmed_authors><pubmed_authors>Osier FHA</pubmed_authors><pubmed_authors>Kamuya D</pubmed_authors><pubmed_authors>Kapulu MC</pubmed_authors><pubmed_authors>Kivisi C</pubmed_authors><pubmed_authors>Ogutu B</pubmed_authors><pubmed_authors>Lowe B</pubmed_authors><pubmed_authors>Hoffman SL</pubmed_authors><pubmed_authors>Billingsley PF</pubmed_authors><pubmed_authors>Ngoto O</pubmed_authors><pubmed_authors>Kimathi R</pubmed_authors><pubmed_authors>de Laurent Z</pubmed_authors><pubmed_authors>Kibinge N</pubmed_authors><pubmed_authors>Musasia FK</pubmed_authors><pubmed_authors>Frank R</pubmed_authors><pubmed_authors>Ngoi JM</pubmed_authors><pubmed_authors>Bull PC</pubmed_authors><pubmed_authors>Muthui M</pubmed_authors><pubmed_authors>Nyangweso G</pubmed_authors><pubmed_authors>Omuoyo D</pubmed_authors><pubmed_authors>Tuju J</pubmed_authors><pubmed_authors>Audi A</pubmed_authors><pubmed_authors>Chi PC</pubmed_authors><pubmed_authors>Ongas MO</pubmed_authors><pubmed_authors>Koskei N</pubmed_authors><pubmed_authors>Shangala J</pubmed_authors><pubmed_authors>Odera DO</pubmed_authors><pubmed_authors>Williams TN</pubmed_authors><pubmed_authors>Musembi J</pubmed_authors><pubmed_authors>Ongecha J</pubmed_authors><pubmed_authors>Otieno E</pubmed_authors><pubmed_authors>Murungi L</pubmed_authors><pubmed_authors>Marsh K</pubmed_authors><pubmed_authors>CHMI-SIKA Study Team</pubmed_authors><pubmed_authors>Musyoki J</pubmed_authors><pubmed_authors>Richie TL</pubmed_authors><pubmed_authors>James ER</pubmed_authors><pubmed_authors>Kamuyu G</pubmed_authors><pubmed_authors>Njue M</pubmed_authors><pubmed_authors>Kimani D</pubmed_authors><pubmed_authors>Kinyanjui S</pubmed_authors><pubmed_authors>Mwacharo J</pubmed_authors><pubmed_authors>Mohammed KS</pubmed_authors><pubmed_authors>Marsh V</pubmed_authors><pubmed_authors>Kariuki S</pubmed_authors><pubmed_authors>Mosobo M</pubmed_authors><pubmed_authors>Furle K</pubmed_authors><pubmed_authors>Mwongeli J</pubmed_authors><pubmed_authors>Sim BKL</pubmed_authors><pubmed_authors>Njuguna P</pubmed_authors><pubmed_authors>Tarning J</pubmed_authors><pubmed_authors>Imwong M</pubmed_authors><pubmed_authors>Jao I</pubmed_authors><pubmed_authors>Olewe F</pubmed_authors><pubmed_authors>Abdi AI</pubmed_authors><pubmed_authors>Chege T</pubmed_authors><pubmed_authors>Wambua J</pubmed_authors><pubmed_authors>Murphy SC</pubmed_authors><pubmed_authors>Abebe Y</pubmed_authors><pubmed_authors>Mwanga D</pubmed_authors><pubmed_authors>Ndungu F</pubmed_authors><pubmed_authors>Oloo J</pubmed_authors><pubmed_authors>Hodgson SH</pubmed_authors><pubmed_authors>Nkumama IN</pubmed_authors><pubmed_authors>Makale J</pubmed_authors><pubmed_authors>Hamaluba M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.</name><description>Natural killer (NK) cells are potent immune effectors that can be activated via antibody-mediated Fc receptor engagement. Using multiparameter flow cytometry, we found that NK cells degranulate and release IFN-γ upon stimulation with antibody-opsonized &lt;i>Plasmodium falciparum&lt;/i> merozoites. Antibody-dependent NK (Ab-NK) activity was largely strain transcending and enhanced invasion inhibition into erythrocytes. Ab-NK was associated with the successful control of parasitemia after experimental malaria challenge in African adults. In an independent cohort study in children, Ab-NK increased with age, was boosted by concurrent &lt;i>P. falciparum&lt;/i> infections, and was associated with a lower risk of clinical episodes of malaria. Nine of the 14 vaccine candidates tested induced Ab-NK, including some less well-characterized antigens: P41, P113, MSP11, RHOPH3, and &lt;i>Pf&lt;/i>_11363200. These data highlight an important role of Ab-NK activity in immunity against malaria and provide a potential mechanism for evaluating vaccine candidates.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2026-06-07T08:14:38.991Z</modification><creation>2025-04-04T23:49:58.374Z</creation></dates><accession>S-EPMC7616656</accession><cross_references><pubmed>36753561</pubmed><doi>10.1126/scitranslmed.abn5993</doi></cross_references></HashMap>